This is where xanomeline-trospium (KarXT) comes in. Xanomeline is a muscarinic M1/M4 agonist that improved Brief Psychiatric Rating Scale (BPRS) and Positive and Negative Syndrome (PANSS) scores in patients with schizophrenia. While gastrointestinal adverse effects limited further clinical development, ultimately, the addition of trospium made xanomeline-trospium viable.
6 Likes